Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Hepatology. Author manuscript; available in PMC 2011 May 1.
Published in final edited form as:
PMCID: PMC2946382

Specific HLA Class I and II Alleles Associated with Hepatitis C Virus Viremia


Studies of human leukocyte antigen (HLA) alleles and their relation with hepatitis C virus (HCV) viremia have had conflicting results. However, these studies have varied in size and methods, and few large studies assessed HLA class I alleles. Only one study conducted high resolution class I genotyping. The current investigation therefore involved high-resolution HLA class I and II genotyping of a large multi-racial cohort of US women with high prevalence of HCV and HIV. Our primary analyses evaluated associations between twelve HLA alleles identified through a critical review of the literature and HCV viremia in 758 HCV-seropositive women. Other alleles with >5% prevalence were also assessed; previously unreported associations were corrected for multiple comparisons. DRB1*0101 (prevalence ratio [PR] = 1.7; 95% confidence interval [CI] = 1.1–2.6), B*5701 (PR=2.0; 95% CI = 1.0–3.1), B*5703 (PR = 1.7; 95% CI = 1.0–2.5), and Cw*0102 (PR = 1.9; 95% CI = 1.0–3.0) were associated with the absence of HCV RNA (i.e., HCV clearance), while DRB1*0301 (PR = 0.4; 95% CI = 0.2–0.7) was associated with HCV RNA positivity. DQB1*0301 was also associated with the absence of HCV RNA but only among HIV-seronegative women (PR = 3.4; 95% CI = 1.2–11.8). Each of these associations was among those predicted. We additionally studied the relation of HLA alleles with HCV infection (serostatus) in women at high risk of HCV from injection drug use (IDU; N=838), but no significant relationships were observed.


HLA genotype influences host capacity to clear HCV viremia. The specific HLA associations observed in the current study are unlikely to be due to chance since they were a priori hypothesized.

Keywords: human leukocyte antigen, HIV, injection drug user, multiple comparisons, killer immunoglobulin-like receptor


Over 4 million women and men in the United States and 150 million people worldwide are estimated to be hepatitis C virus (HCV) seropositive.(1;2) Most of these individuals are chronically infected with the virus and are at high risk of cirrhosis, hepatocellular carcinoma, and liver-related death. The natural history of HCV infection however is highly variable. Some individuals do not become HCV infected despite high levels of exposure.(3) Other individuals may clear HCV RNA following acute infection, and while some individuals with long-term HCV viremia remain clinically asymptomatic, others have progressive disease.(4) Indeed, marked variability in natural history is seen even among groups of individuals with single source exposure to HCV, as occurred in a population of Irish women exposed to HCV-contaminated anti-D immune globulin.(5) Together these observations suggest that host factors, particularly host immune response, play a key role in the regulation of HCV pathogenesis.

Human leukocyte antigen (HLA) genes are critical to the regulation of both cellular and innate immunity and are among the most polymorphic in the human genome. HLA genes are clustered together on the short arm of chromosome 6 and encode HLA molecules that form stable complexes when bound to foreign peptides. These complexes are presented on cell surfaces where they are recognized and bound by T-cells initiating a cascade of immune responses capable of clearing foreign material. The diversity of HLA variants, or alleles, is a critical factor in the ability of HLA to bind a wide variety of antigens, and for the immune system to respond to a wide variety of pathogens.

Several strong associations between HLA alleles and infectious agents have been reported, and recent genome-wide association studies of HIV disease progression have provided further evidence of the importance of HLA polymorphism in host control of viral infections. Over forty studies have examined the relationship between HLA alleles and HCV natural history (reviewed in (6;7)) but many of these studies have been small and/or had important limitations (e.g. absence of a control group). In addition, despite the major role of class I HLA-restricted T-cell responses in the control of HCV pathogenesis,(8;9) few studies have examined associations between HCV natural history and HLA class I alleles.(1015) Among the studies that did examine HLA class I alleles, several interesting findings have been reported, but the results were inconsistent across studies. Only one of these studies utilized high resolution genotyping of class I alleles.(12) Lastly, there are also few data regarding associations between HLA alleles and risk of initial HCV infection (HCV seropositivity) in highly exposed populations.(1618)

To address these issues we conducted high-resolution HLA class I and II genotyping in a large multi-racial population of US women with a high prevalence of HCV and HIV infection. Furthermore, we focused primarily on associations between HCV disease phenotypes and a narrow set of a priori-defined HLA alleles identified as part of a critical review of the literature. By specifying in advance those associations with the highest prior probability, we intended to reduce concerns regarding multiple comparisons a major difficulty for the interpretation of HLA data due to the large number of distinct HLA alleles and to make this study largely an assessment of a small number of discrete hypothesized relationships.


Review of the HCV-HLA Literature

We searched the PubMed database using the search string “hepatitis C” and “HLA” (or “human leukocyte antigen”). We limited our search to epidemiologic studies focused on the associations of HLA alleles with (i) HCV viremia (i.e. presence/absence of HCV RNA) among HCV-seropositive individuals, or (ii) HCV infection (i.e. serostatus) in high-risk populations, and to studies published in English. We additionally examined the references cited in each paper, including several review papers.(6;7;19;20)

We then critically evaluated the identified studies for the appropriateness of their research design (e.g. existence of a suitable comparison group, adequacy of sample size) and statistical methods. Based on this evaluation we constructed a list of HLA class II alleles (4 digit resolution) and allele groups (2 digit resolution) associated with HCV viremia or HCV infection that had been reported in at least two studies that in our subjective view had been appropriately conducted. Alleles and allele groups meeting these criteria were considered to have a high prior probability of association with one or both of the HCV phenotypes of interest.

Because there was much less data reported regarding associations between HCV and HLA class I alleles (compared to class II alleles) we set a slightly less stringent threshold for designating class I alleles as having a high prior probability of association with HCV. Specifically, an HLA class I HCV association could either have (as above for class II) been reported in at least two prior studies, or it could have had a particularly strong (i.e., an odds ratio greater than or equal to 3.0) relationship with HCV in one prior study. This odds ratio threshold was selected since threefold and greater risks are considered to be strong and less likely to be due to confounding.(21)

Our review identified six HLA class II alleles and three HLA class I allele groups associated with HCV viremia in two or more studies. An additional two HLA class I allele groups were strongly associated (OR>3.0) with HCV viremia in a single study (shown in Table 1). In contrast to HCV viremia, however, we found only three studies that examined the relation of HCV serostatus with HLA alleles in high-risk populations(1618) and there were no consistent or strong findings among these three studies.

Table 1
HLA Alleles and Allele Groups with a High Prior Probability of Association with HCV Viremia *

Study Population

The Women's Interagency HIV Study (WIHS) is a prospective, multicenter cohort study of HIV-seropositive (N=2,793) and HIV-seronegative (N=975) women enrolled through similar sources at six clinical sites (Bronx, NY; Brooklyn, NY; Chicago, IL; Los Angeles, CA; San Francisco, CA; and Washington, DC). The initial enrollment was conducted between October 1994 and November 1995, and a subsequent second recruitment cycle occurred in 2002. The recruitment methods and data collection procedures for WIHS have been described previously.(22) Briefly, subjects in this ongoing study are evaluated every 6 months with standardized interviews, physical examination, and a blood draw. The WIHS protocol was approved by each local institutional review board, and all participants signed informed consent.

In the current investigation we focused on WIHS women who, at the enrollment visit, had either self-reported a history of injection drug use (IDU) and were therefore considered at high risk of HCV infection and/or were HCV seropositive. Among HCV seropostive women (N=1,204) we limited our analysis to women with known HCV RNA status (N=1,070), self-reported White non-Hispanic, Black non-Hispanic, or Hispanic race/ethnicity (N=1,046), and had complete HLA data at one or more HLA loci (N=758). Among the IDU (N=1,161), we limited our analyses to women with known HCV serostatus (N=1,129), self-reported White non-Hispanic, Black non-Hispanic, or Hispanic race/ethnicity (N=1,098), and had complete HLA data at one or more HLA loci (N=838).

Laboratory Methods

HCV Testing

HCV serostatus was determined in all WIHS subjects at enrollment using a commercial second or third-generation enzyme immunoassay. HCV viremia was determined for HCV-seropositive women using either the COBAS Amplicor Monitor 2.0, which has a linear range of 600 5.0 × 105 IU/ml, as previously described,(23) or the COBAS Taqman assay, which has a linear range of 10 2.0 × 108 IU/ml (both from Roche Diagnostics, Branchburg, New Jersey, USA). Previous testing demonstrated a high correlation of HCV RNA levels in the two assays, and a 10% resample of patients with undetectable HCV RNA in the Amplicor assay were also undetectable in the TaqMan assay (data not shown). HCV genotyping was conducted on a subset of HCV viremic women using the NC TRUGENE HCV 5 NC Genotyping Kit (Bayer HealthCare LLC, Tarrytown, NY), as previously described.(24)

HLA Genotyping

Genomic DNA was prepared from subjects’ lymphoblastoid B cell lines or from peripheral blood lymphocytes. Protocols for HLA genotyping have been standardized through the International Histocompatibility Working Group ( Briefly, HLA class I genes (HLA-A, −B, and −C) were amplified using locus-specific PCR primers flanking exons 2 and 3, the polymorphic segments of the class I genes. The 1 kb PCR products were blotted on nylon membranes and hybridized with a panel of sequence-specific oligonucleotide (SSO) probes. The HLA alleles were assigned by the reaction patterns of the SSO probes, according to known HLA sequences. Any ambiguous SSO probing was resolved by sequencing analysis, as previously described.(25) HLA class II typing was conducted using high resolution SSO typing for HLA-DQA, −DQB, and −DRB1 loci, using the polymorphic exon 2. DRB genotyping involved a two-step procedure. First, the broad serological DR types were determined using a pair of DRB generic primers and a panel of SSO probes. Allele-level DRB typing was then achieved by using group-specific primers to amplify the DRB alleles determined in the generic typing followed by SSO hybridization. For DQA and DQB, locus-specific PCR were performed followed by SSO hybridization.

Statistical Methods

Descriptive statistics for demographic and clinical variables were calculated for the HCV-seropositive women and the IDU. We examined differences in these characteristics between HCV RNA-positive versus HCV RNA-negative women and between HCV-seropositive versus HCV-seronegative women using the T-test (for continuous data), Mann-Whitney U test (for continuous data with small subgroups), chi-square test (for categorical data), and Fisher’s exact test (for categorical data with small subgroups).

The principal analyses focused on the associations between HLA alleles and HCV viremia among HCV-seropositive women and between HLA alleles and HCV infection (serostatus) among women who reported IDU. In our a priori-planned analyses of HLA alleles with a high prior probability of association with HCV viremia, we included those alleles present in at least 3% of the women studied (i.e., 23 or more of the 758 HCV seropositive women heterozygous or homozygous for a given allele). In our exploratory analyses, which examined alleles without a high prior probability of association (i.e., alleles not included in Table 1) we focused on alleles that had at least 5% prevalence, since exploratory analyses are more prone to spurious findings (particularly when data are limited). Our analyses employed log-binomial regression models to calculate both unadjusted and race/ethnicity-adjusted prevalence ratios. However, when assessing alleles without a high prior probability of association (i.e. alleles not included in Table 1) we corrected the P-values for multiple comparisons via permutation resampling using PROC MULTTEST; a method that empirically incorporates correlations within and between loci.(26)

Because some prior studies have described variation in HLA associations by race,(27;28) we assessed potential heterogeneity in effect estimates (i.e. interaction) by race/ethnicity. In contrast, we did not expect to observe heterogeneity by HIV-serostatus or CD4+ T-cell count among HIV-seropositive women. A variety of sources suggest that HCV infection generally occurs prior to HIV infection in new IDU,(2931) and therefore that the majority HCV RNA clearance/persistence occurs without relation to HIV. It is possible, however, that HIV preceded HCV infection in some women. For completeness, therefore, we assessed heterogeneity by HIV serostatus/CD4+ T-cell count (HIV-seronegative, HIV-seropositive with CD4+ T-cell count ≥ 500 cells/mm3, and HIV-seropositive with CD4+ T-cell count < 500 cells/mm3). Lastly, we examined whether groups of HLA alleles that act as ligand for killer immunoglobulin-like receptors (KIR) were associated with HCV infection and HCV viremia. KIR play a major role in the activation of natural killer (NK) cells and the innate immune response and specific combinations of KIR and HLA ligands have been associated with clearance of HCV RNA previously.(32;33) These ligand groups were Bw4 reflecting 141 HLA-B alleles, Cw group 1 reflecting 48 HLA-Cw alleles, and Cw group 2 reflecting 43 HLA-Cw alleles.(32) All statistical analyses were performed using SAS 9.1 (SAS Institute, Inc., Cary, NC).


Demographic and Clinical Characteristics of the Study Population

Selected characteristics of the 758 HCV-seropositive women with and without detectable HCV RNA are shown in Table 2a. Most HCV-seropositive women reported IDU, and this did not vary according to HCV RNA positivity. The HCV RNA-positive women, though, were more likely than those who were HCV RNA-negative to be Black, non-Hispanic. HIV-seroprevalence did not differ between HCV RNA-positive/-negative women, but the CD4+ T-cell counts were significantly lower among those HIV-seropositives who had detectable HCV RNA. HCV genotype was determined for 226 of the women with detectable HCV viremia. The genotype distribution among these women was: 1a in 125 (55%) of the 226 women; 1b in 65 (29%); type 1 but with undetermined subtype in 8 (4%); 2a in 3 (1%); 2b in 6 (3%); 3a in 14 (6%); 3d in 1 (<1%); and 4a in 4 (2%) women.

Table 2
Demographic and Clinical Characteristics of the Study Population

Table 2b shows selected characteristics of the 838 IDUs with/without HCV infection (there was substantial, but not complete, overlap between the injection drug users evaluated to study association with HCV infection, and the HCV-seropositive women evaluated to study association with HCV viremia). HCV-seropositive IDU were older, more likely to be Black, non-Hispanic, and more likely to be HIV-seropositive than HCV-seronegative IDU. CD4+ T-cell counts were similar however between HIV infected HCV-seropositive and HCV-seronegative IDU.

HLA Alleles Associated with HCV Viremia in HCV-Seropositive Women

Our review of the HCV-HLA epidemiologic literature identified six class II alleles (4 digit resolution) and five class I allele groups (2 digit resolution) with a high prior probability of association with detectable HCV RNA (Table 1). Each of the six class II alleles had >3% prevalence among the HCV-seropositive subjects. The five class I allele groups were largely reflective of a single (4 digit) allele with >3% prevalence, except for the B*57 group which had two alleles with >3% prevalence (Table 3a). Therefore, a total of twelve individual alleles with a high prior probability of association with HCV viremia were included in our primary analyses of HCV clearance.

Table 3
HLA Alleles and Their Associations with HCV Viremia among HCV-Seropositive Women

Of these twelve HLA alleles, six were found to have the predicted associations with detectable HCV RNA in both unadjusted and adjusted (for race/ethnicity) analyses. Specifically, DRB1*0101 (prevalence ratio [PR] = 1.7; 95% confidence interval [CI] = 1.1–2.6), B*5701 (PR = 2.0; 95% CI = 1.0–3.1), B*5703 (PR = 1.7; 95% CI = 1.0–2.5), and Cw*0102 (PR = 1.9; 95% CI = 1.0–3.0) were each associated with absence of HCV RNA (i.e., HCV clearance) in adjusted analysis, as was the B*57 allele group (PR =1.7; 95% CI = 1.1–2.4) as a whole. DRB1*0301 (OR = 0.4; 95% CI=0.2–0.7) in contrast was associated with the presence of HCV RNA. For a sixth allele with high prior probability of association, DQB1*0301, we observed significant statistical interaction by HIV serostatus/CD4+ T-cell count (Pinteraction = 0.02). Only among HIV- seronegative women (PR = 3.4; 95% CI = 1.2–11.8), and not among HIV-seropositive women with CD4+ T-cell count ≥ 500 cells/mm3 (PR = 0.6; 95% CI = 0.2–1.4) or HIV-seropositive women with CD4+ T-cell count < 500 cells/mm3 (PR = 1.7; 95% CI = 0.8–3.3) was there a significant association with between DQB1*0301 and HCV viremia. In contrast, there were no significant associations between HCV viremia and the other six alleles with high prior probability of association, namely, DRB1*0401, DRB1*1101, DRB1*1501, B*1801, B*2705, and Cw*0401.

Exploratory analyses of the 58 additional HLA class I and II alleles (which lacked a high prior probability of association) identified two additional alleles that were significantly associated with HCV viremia: DRB1*0701 and DRB1*1302 (see Supplementary Table 1). However, as seen in Table 3b, these allele associations became statistically non-significant after adjustment for multiple comparisons. We also studied associations with three broad groups of HLA class I alleles that can act as ligand for KIR, namely, Bw4, Cw group 1, and Cw group 2. Specifically, as in prior reports, we tested whether homozygosity for a given KIR ligand group (e.g., a woman with two Cw group 1 alleles) was associated with HCV viremia (32;33), but in our dataset no significant relationships were observed with KIR ligand groups.

HLA Alleles Associated with HCV Infection in Injection Drug Users

Our review of the HCV-HLA literature identified only three studies of HLA alleles and HCV serostatus in high-risk populations(1618) and there were no consistent findings or strong associations. We therefore treated all of the analysis of HCV serostatus and HLA alleles as exploratory, and all significant P-values were adjusted for multiple comparisons. Of the 64 HLA class I and II alleles with > 5% prevalence in the 838 IDUs studied, B*5703 (P = 0.03), Cw*0304 (P = 0.04), and Cw*0701 (P = 0.01), were significantly associated with HCV infection (see Supplementary Table 2), but these associations did not retain significance after adjustment for multiple comparisons (P = 0.99, 1.0, and 0.64 respectively). There were no significant interactions by race/ethnicity or HIV serostatus/CD4+ T-cell count.


We studied the relation of high-resolution HLA class I and II genotype with HCV viremia, and with HCV serostatus in injection drug users (IDU). While there have been a number of prior studies of HLA alleles and HCV viremia, many of the findings to date have been conflicting. Part of this variability may relate to aspects of study design, including differences in sample size, and whether an appropriate control group was used. Furthermore, few studies examined HLA class I alleles, with only one having conducted high resolution class I genotyping.(12) There has also been very little data regarding HLA and the prevalence of HCV infection (i.e. seropositivity) in high-risk populations.(1618) To build upon the existing data, therefore, we conducted high-resolution HLA class I and II genotyping in a large multi-racial cohort of US women with high prevalence of HCV and HIV infection.

Several significant associations between HLA class I and II alleles and HCV viremia were observed. These included six of the twelve HLA alleles that we identified as having a high prior probability of association with HCV viremia based on a critical review of the literature. Because each of these associations represented discrete a priori hypotheses it is unlikely that they occurred by chance.

Both B*5701 and B*5703, for example, were significantly associated with absence of HCV RNA. Two earlier studies of HLA class I had reported similar associations with the B*57 allele group; the first was conducted in a large multi-racial, majority male population in the US,(12) while the second was conducted in a small, majority male population in West Africa.(13) A third study conducted in Ireland also found an association between the B*57 allele group and HCV viremia, though the results did not attain statistical significance.(14) In the current study the relation of the B*57 allele group with HCV viremia mainly reflected the combined effects of B*5701 and B*5703, but we caution that our dataset included too few women with other B*57 alleles (e.g. B*5702, B*5704) to study in detail.

It is interesting to note that B*5701 and B*5703 also appear to have a diverse range of other effects on host immune response. B*5701 for example has been associated with slow HIV disease progression,(34;35) as well as with abacavir hypersensitivity,(36) and with the autoimmune conditions psoriasis and psoriatic arthritis.(37) B*5703 is also associated with slow HIV disease progression(38) and with the autoimmune condition spondylarthropathy.(39) These associations could reflect the antigen binding characteristics of these alleles. However, an alternative or additional possibility is that the broad impact of B*5701 and B*5703 is explained by their ability to act as ligand for killer immunoglobulin-like receptors (KIR); receptors which help modulate the activation of NK cells and the innate immune system. Indeed, it has been reported that the B*57 group may be a particularly strong KIR ligand.(40) Although we did not observe a significant association between HCV viremia and the broader groups of alleles that act as ligand for KIR, KIR genotyping of our population will be needed to study this issue more comprehensively.

Similarly, DRB1*0101, DQB1*0301, Cw*0102, and DRB1*0301 were associated with HCV viremia in this and the other epidemiologic studies identified in Table 1, and may also be associated with various autoimmune conditions. DRB1*0101 and DQB1*0301 are reported to be risk factors for the autoimmune condition rheumatoid arthritis,(41;42) while Cw*0102 is associated with both psoriasis(43) and autoimmune hepatitis.(44) Cw*0102, like HLA*B57, can act as ligand for KIR.(45) Lastly, DRB1*0301 is inversely associated with rheumatoid arthritis,(46) consistent with its inverse association with HCV clearance, though we note it also has positive associations with autoimmune hepatitis(47) and systemic lupus erythematosus.(48)

The fact that both B*57 and Cw*01 can act as ligand for KIR could help explain their broad range of immunologic associations, since NK cells are not antigen-specific. However, we are unaware of any characteristics of the HLA class II alleles that might readily explain their mutual associations with both HCV viremia and autoimmune disease.

Six expected associations between HLA alleles and HCV viremia were not observed. Specifically, there were no significant relationships of DRB1*0401, DRB1*1101, DRB1*1501, B*1801, B*2705, or Cw*0401 with the presence/absence of HCV RNA despite their high prior probability of association based on earlier reports. The failure to replicate these predicted associations could have several explanations. First, in our study the vast majority of HCV infections were genotype 1, whereas in Europe genotypes 3 and 4 are also common;(49) i.e., differences in genotype-specific protein expression may affect HLA-restricted immune responses.(50) Differences in host characteristics could also explain the conflicting findings, such as differences in the prevalence of certain alleles. For example, in our population both DRB1*0401 and B*2705 were rare, and thus we had limited statistical power to examine associations with these alleles. There could also be differences in patterns of linkage disequilibrium between loci in different populations.

In contrast to HCV viremia, we found no significant associations of HLA alleles with HCV infection in high-risk women. We note that compared with the substantial literature regarding HCV viremia and HLA there has been little published data regarding HCV serostatus and HLA. To our knowledge, only three prior studies have been reported,(1618) and they had conflicting results. With so little prior data for comparison we are unable to fully judge our null findings for HCV serostatus. It is interesting that prior to adjustment for multiple comparisons, B*5703, Cw*0304, and Cw*0701 were significantly associated with HCV infection among the women who reported IDU, but these associations were not reported in the three earlier studies. Therefore, while it might seem unlikely for there to be no associations at all between HLA alleles and the risk of HCV infection, it remains that there have been no reproducible associations observed to date.

This study had several limitations that must be considered in the interpretation of these data. One of the most important limitations was the lack of individualized data regarding the actual level of exposure to HCV which is needed to comprehensively assess the associations between HCV serostatus and HLA alleles. The fact that the women all reported IDU only identifies them as being in a high-risk group. Data regarding frequency of IDU, frequency of needle sharing, and whether IDU took place in a high-risk context (e.g. a shooting gallery) were unavailable in this study. On the other hand, our analysis of HCV RNA clearance was unlikely to be affected by issues of HCV exposure since all of the women analyzed were HCV-seropositive. The major limitation of our analysis of HCV viremia was sample size. Although this study was large compared with many prior reports, we still lacked the statistical power to study associations between HCV phenotypes and uncommon alleles. Given that our study population was largely Black and Hispanic, this applied especially to alleles that are mainly common among White, non-Hispanic populations. Lastly, as in all genetic association studies, the associations we observed could relate to the alleles we assessed, or to linkage disequilibrium with unexamined genetic markers.

In summary, the current study provides new evidence that a small number of specific HLA alleles may be important mediators of host capacity to clear HCV infection. These results are unlikely to be due to chance since each of the associations had been a priori predicted based on a critical review of the literature. We additionally recognized that each of the alleles related to HCV viremia in this study has also been associated with one or more autoimmune conditions. Additional epidemiologic and laboratory studies to characterize the properties of these alleles is warranted, with the hope that knowledge of the factors involved in an effective immune response can be exploited in the development of novel HCV prevention and treatment strategies.

Supplementary Material


Financial Support:

Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). Additional funding for this project was provided by a grant from the National Institute of Allergy and Infectious Diseases (5R01AI057006-04 to H.D.S.). This project has been funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

List of Abbreviations

human leukocyte antigen
hepatitis C virus
prevalence ratio
confidence interval
injection drug use
Women's Interagency HIV Study
sequence-specific oligonucleotide
killer immunoglobulin-like receptor
natural killer



The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

Potential conflict of interest:

Dr. Terrault has received research grants from Roche, Vertex, and Human Genome Sciences. All other authors, no conflicts.


1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714. [PubMed]
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 (Suppl 1):74–81. [PubMed]
3. Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, et al. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198:1749–1755. [PubMed]
4. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis. 2005;9:383–98. vi. [PubMed]
5. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–1233. [PubMed]
6. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol. 2007;13:1770–1787. [PubMed]
7. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun. 2004;5:237–245. [PubMed]
8. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395–1406. [PMC free article] [PubMed]
9. Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L, et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology. 2006;44:126–139. [PubMed]
10. Kuzushita N, Hayashi N, Moribe T, Katayama K, Kanto T, Nakatani S, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology. 1998;27:240–244. [PubMed]
11. Lopez-Vazquez A, Rodrigo L, Mina-Blanco A, Martinez-Borra J, Fuentes D, Rodriguez M, et al. Extended human leukocyte antigen haplotype EH18.1 influences progression to hepatocellular carcinoma in patients with hepatitis C virus infection. J Infect Dis. 2004;189:957–963. [PubMed]
12. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. HLA-Cw*04 and hepatitis C virus persistence. J Virol. 2002;76:4792–4797. [PMC free article] [PubMed]
13. Chuang WC, Sarkodie F, Brown CJ, Owusu-Ofori S, Brown J, Li C, et al. Protective effect of HLA-B57 on HCV genotype 2 infection in a West African population. J Med Virol. 2007;79:724–733. [PubMed]
14. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology. 2004;40:108–114. [PubMed]
15. Fanning LJ, Kenny-Walsh E, Shanahan F. Persistence of hepatitis C virus in a white population: associations with human leukocyte antigen class 1. Hum Immunol. 2004;65:745–751. [PubMed]
16. Congia M, Clemente MG, Dessi C, Cucca F, Mazzoleni AP, Frau F, et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology. 1996;24:1338–1341. [PubMed]
17. Verdon R, Pol S, Landais P, Mattlinger B, Carnot F, Brechot C, et al. Absence of association between HLA antigens and chronicity of viral hepatitis in haemodialyzed patients. J Hepatol. 1994;21:388–393. [PubMed]
18. Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology. 2007;46:1713–1721. [PubMed]
19. Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun. 2007;8:181–192. [PubMed]
20. Thio CL. Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis. 2008;12:713–26. xi. [PMC free article] [PubMed]
21. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA. 1999;281:841–844. [PubMed]
22. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117–125. [PubMed]
23. Al-Harthi L, Voris J, Du W, Wright D, Nowicki M, Frederick T, et al. Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis. 2006;193:1202–1210. [PMC free article] [PubMed]
24. Laskus T, Wilkinson J, Karim R, Mack W, Radkowski M, deGiacomo M, et al. Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART) Hepatology. 2007;46:359–370. [PMC free article] [PubMed]
25. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med. 2001;344:1668–1675. [PubMed]
26. Westfall PH, Young SS. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. Wiley-Interscience; 1993.
27. Harris RA, Sugimoto K, Kaplan DE, Ikeda F, Kamoun M, Chang KM. Human leukocyte antigen class II associations with hepatitis C virus clearance and virus-specific CD4 T cell response among Caucasians and African Americans. Hepatology. 2008;48:70–79. [PMC free article] [PubMed]
28. Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis. 2001;184:16–21. [PubMed]
29. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655–661. [PubMed]
30. Garten RJ, Lai S, Zhang J, Liu W, Chen J, Vlahov D, et al. Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol. 2004;33:182–188. [PubMed]
31. Sutton AJ, Hope VD, Mathei C, Mravcik V, Sebakova H, Vallejo F, et al. A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. J Viral Hepat. 2008;15:809–816. [PubMed]
32. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305:872–874. [PubMed]
33. Romero V, Azocar J, Zuniga J, Clavijo OP, Terreros D, Gu X, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol. 2008;45:2429–2436. [PMC free article] [PubMed]
34. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science. 2007;317:944–947. [PMC free article] [PubMed]
35. Gao X, Bashirova A, Iversen AK, Phair J, Goedert JJ, Buchbinder S, et al. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med. 2005;11:1290–1292. [PubMed]
36. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–1118. [PubMed]
37. Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 2008;4:e1000041. [PMC free article] [PubMed]
38. Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, Allen S, et al. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women. AIDS. 1999;13:1990–1991. [PubMed]
39. Lopez-Larrea C, Njobvu PD, Gonzalez S, Blanco-Gelaz MA, Martinez-Borra J, Lopez-Vazquez A. The HLA-B*5703 allele confers susceptibility to the development of spondylarthropathies in Zambian human immunodeficiency virus-infected patients with slow progression to acquired immunodeficiency syndrome. Arthritis Rheum. 2005;52:275–279. [PubMed]
40. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet. 2007;39:733–740. [PubMed]
41. Gonzalez-Gay MA, Garcia-Porrua C, Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum. 2002;31:355–360. [PubMed]
42. Zanelli E, Breedveld FC, de Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum Immunol. 2000;61:1254–1261. [PubMed]
43. Romphruk AV, Romphruk A, Choonhakarn C, Puapairoj C, Inoko H, Leelayuwat C. Major histocompatibility complex class I chain-related gene A in Thai psoriasis patients: MICA association as a part of human leukocyte antigen-B-Cw haplotypes. Tissue Antigens. 2004;63:547–554. [PubMed]
44. Shankarkumar U, Amarapurkar DN, Kankonkar S. Human leukocyte antigen allele associations in type-1 autoimmune hepatitis patients from western India. J Gastroenterol Hepatol. 2005;20:193–197. [PubMed]
45. Williams AP, Bateman AR, Khakoo SI. Hanging in the balance. KIR and their role in disease. Mol Interv. 2005;5:226–240. [PubMed]
46. Jun KR, Choi SE, Cha CH, Oh HB, Heo YS, Ahn HY, et al. Meta-analysis of the association between HLA-DRB1 allele and rheumatoid arthritis susceptibility in Asian populations. J Korean Med Sci. 2007;22:973–980. [PMC free article] [PubMed]
47. Czaja AJ. Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2008;6:379–388. [PubMed]
48. Fernando MM, Stevens CR, Sabeti PC, Walsh EC, McWhinnie AJ, Shah A, et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genet. 2007;3:e192. [PubMed]
49. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008;198:1337–1344. [PubMed]
50. Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmaurice K, Oniangue C, et al. The protective effect of HLA-B27 in hepatitis C virus infection requires presence of a genotype-specific immunodominant CD8+ T cell epitope. Hepatology. 2009;9999:NA. [PubMed]
51. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology. 1997;113:1675–1681. [PubMed]
52. Cramp ME, Carucci P, Underhill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol. 1998;29:207–213. [PubMed]
53. Mangia A, Gentile R, Cascavilla I, Margaglione M, Villani MR, Stella F, et al. HLA class II favors clearance of HCV infection and progression of the chronic liver damage. J Hepatol. 1999;30:984–989. [PubMed]
54. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis. 1998;178:39–44. [PubMed]
55. Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999;354:2119–2124. [PubMed]
56. Alric L, Fort M, Izopet J, Vinel JP, Bureau C, Sandre K, et al. Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens. 2000;56:154–158. [PubMed]
57. Fanning LJ, Levis J, Kenny-Walsh E, Wynne F, Whelton M, Shanahan F. Viral clearance in hepatitis C (1b) infection: relationship with human leukocyte antigen class II in a homogeneous population. Hepatology. 2000;31:1334–1337. [PubMed]
58. Barrett S, Goh J, Coughlan B, Ryan E, Stewart S, Cockram A, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut. 2001;49:423–430. [PMC free article] [PubMed]
59. Lechmann M, Schneider EM, Giers G, Kaiser R, Dumoulin FL, Sauerbruch T, et al. Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest. 1999;29:337–343. [PubMed]